🔴 Vera Therapeutics is trading 4.04% down today despite positive TRUTAKNA Phase 3 results

Vera Therapeutics is trading 4.04% down at $32.31 after reversing gains from September 15’s positive TRUTAKNA Phase 3 results.

• The ORIGIN 3 study met all prespecified endpoints.
• The stock has continued weakening despite the favorable announcement, consistent with profit-taking and broader biotech pressure.
• The biotech-sector ETF XBI is down 2.11% during regular trading, providing the clearest same-day directional context.